Management of Peristomal Pyoderma Gangrenosum

Lisa Poritz, Marjorie A. Lebo, Anne D. Bobb, Christine M. Ardell, Walter Koltun

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: Pyoderma gangrenosum (PG) occurs in about 1% to 5% of patients with inflammatory bowel disease (IBD). Peristomal pyoderma gangrenosum (PPG) is particularly difficult to manage. Study Design: A retrospective chart review was performed on all patients with IBD in whom PPG developed from 1997 to 2007 at the Milton S Hershey Medical Center. Results: Sixteen patients (11 women) were identified. Seven had Crohn's disease (CD), seven had ulcerative colitis (UC), and two had indeterminate colitis. Six patients underwent total proctocolectomy, six patients had total abdominal colectomy (TAC), and four patients had diverting loop stomas. PPG occurred an average of 18.4 ± 7.5 months after stoma creation. Twelve patients had active IBD when PPG developed. Two patients had stoma revisions and both had recurrence of the PPG with the new stoma. Medical therapy was successful in eight patients. Five patients had their stomas closed, with active PPG, and all five resolved their lesions. In four of five, surgical management was altered because of PPG (one early stoma closure, two ileal pouches without stomas, one ileal pouch with high body mass index). Of the seven and six patients treated with cyclosporine or infliximab, respectively, there were only two successes with each. Conclusions: PPG is more common in the presence of active IBD. Surgical closure of the stoma was successful in resolving PPG in all patients. Cure rate of PPG was poor with cyclosporine and only marginally better with infliximab. Medical treatment of PPG is imperfect, and the best therapy is stoma closure when possible.

Original languageEnglish (US)
Pages (from-to)311-315
Number of pages5
JournalJournal of the American College of Surgeons
Volume206
Issue number2
DOIs
StatePublished - Feb 1 2008

Fingerprint

Pyoderma Gangrenosum
Inflammatory Bowel Diseases
Colonic Pouches
Surgical Stomas
Cyclosporine
Colectomy
Colitis
Ulcerative Colitis
Crohn Disease

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Poritz, Lisa ; Lebo, Marjorie A. ; Bobb, Anne D. ; Ardell, Christine M. ; Koltun, Walter. / Management of Peristomal Pyoderma Gangrenosum. In: Journal of the American College of Surgeons. 2008 ; Vol. 206, No. 2. pp. 311-315.
@article{3581a73d4e7b41bea61d86539d0ddc2f,
title = "Management of Peristomal Pyoderma Gangrenosum",
abstract = "Background: Pyoderma gangrenosum (PG) occurs in about 1{\%} to 5{\%} of patients with inflammatory bowel disease (IBD). Peristomal pyoderma gangrenosum (PPG) is particularly difficult to manage. Study Design: A retrospective chart review was performed on all patients with IBD in whom PPG developed from 1997 to 2007 at the Milton S Hershey Medical Center. Results: Sixteen patients (11 women) were identified. Seven had Crohn's disease (CD), seven had ulcerative colitis (UC), and two had indeterminate colitis. Six patients underwent total proctocolectomy, six patients had total abdominal colectomy (TAC), and four patients had diverting loop stomas. PPG occurred an average of 18.4 ± 7.5 months after stoma creation. Twelve patients had active IBD when PPG developed. Two patients had stoma revisions and both had recurrence of the PPG with the new stoma. Medical therapy was successful in eight patients. Five patients had their stomas closed, with active PPG, and all five resolved their lesions. In four of five, surgical management was altered because of PPG (one early stoma closure, two ileal pouches without stomas, one ileal pouch with high body mass index). Of the seven and six patients treated with cyclosporine or infliximab, respectively, there were only two successes with each. Conclusions: PPG is more common in the presence of active IBD. Surgical closure of the stoma was successful in resolving PPG in all patients. Cure rate of PPG was poor with cyclosporine and only marginally better with infliximab. Medical treatment of PPG is imperfect, and the best therapy is stoma closure when possible.",
author = "Lisa Poritz and Lebo, {Marjorie A.} and Bobb, {Anne D.} and Ardell, {Christine M.} and Walter Koltun",
year = "2008",
month = "2",
day = "1",
doi = "10.1016/j.jamcollsurg.2007.07.023",
language = "English (US)",
volume = "206",
pages = "311--315",
journal = "Journal of the American College of Surgeons",
issn = "1072-7515",
publisher = "Elsevier Inc.",
number = "2",

}

Management of Peristomal Pyoderma Gangrenosum. / Poritz, Lisa; Lebo, Marjorie A.; Bobb, Anne D.; Ardell, Christine M.; Koltun, Walter.

In: Journal of the American College of Surgeons, Vol. 206, No. 2, 01.02.2008, p. 311-315.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Management of Peristomal Pyoderma Gangrenosum

AU - Poritz, Lisa

AU - Lebo, Marjorie A.

AU - Bobb, Anne D.

AU - Ardell, Christine M.

AU - Koltun, Walter

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Background: Pyoderma gangrenosum (PG) occurs in about 1% to 5% of patients with inflammatory bowel disease (IBD). Peristomal pyoderma gangrenosum (PPG) is particularly difficult to manage. Study Design: A retrospective chart review was performed on all patients with IBD in whom PPG developed from 1997 to 2007 at the Milton S Hershey Medical Center. Results: Sixteen patients (11 women) were identified. Seven had Crohn's disease (CD), seven had ulcerative colitis (UC), and two had indeterminate colitis. Six patients underwent total proctocolectomy, six patients had total abdominal colectomy (TAC), and four patients had diverting loop stomas. PPG occurred an average of 18.4 ± 7.5 months after stoma creation. Twelve patients had active IBD when PPG developed. Two patients had stoma revisions and both had recurrence of the PPG with the new stoma. Medical therapy was successful in eight patients. Five patients had their stomas closed, with active PPG, and all five resolved their lesions. In four of five, surgical management was altered because of PPG (one early stoma closure, two ileal pouches without stomas, one ileal pouch with high body mass index). Of the seven and six patients treated with cyclosporine or infliximab, respectively, there were only two successes with each. Conclusions: PPG is more common in the presence of active IBD. Surgical closure of the stoma was successful in resolving PPG in all patients. Cure rate of PPG was poor with cyclosporine and only marginally better with infliximab. Medical treatment of PPG is imperfect, and the best therapy is stoma closure when possible.

AB - Background: Pyoderma gangrenosum (PG) occurs in about 1% to 5% of patients with inflammatory bowel disease (IBD). Peristomal pyoderma gangrenosum (PPG) is particularly difficult to manage. Study Design: A retrospective chart review was performed on all patients with IBD in whom PPG developed from 1997 to 2007 at the Milton S Hershey Medical Center. Results: Sixteen patients (11 women) were identified. Seven had Crohn's disease (CD), seven had ulcerative colitis (UC), and two had indeterminate colitis. Six patients underwent total proctocolectomy, six patients had total abdominal colectomy (TAC), and four patients had diverting loop stomas. PPG occurred an average of 18.4 ± 7.5 months after stoma creation. Twelve patients had active IBD when PPG developed. Two patients had stoma revisions and both had recurrence of the PPG with the new stoma. Medical therapy was successful in eight patients. Five patients had their stomas closed, with active PPG, and all five resolved their lesions. In four of five, surgical management was altered because of PPG (one early stoma closure, two ileal pouches without stomas, one ileal pouch with high body mass index). Of the seven and six patients treated with cyclosporine or infliximab, respectively, there were only two successes with each. Conclusions: PPG is more common in the presence of active IBD. Surgical closure of the stoma was successful in resolving PPG in all patients. Cure rate of PPG was poor with cyclosporine and only marginally better with infliximab. Medical treatment of PPG is imperfect, and the best therapy is stoma closure when possible.

UR - http://www.scopus.com/inward/record.url?scp=38349189772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349189772&partnerID=8YFLogxK

U2 - 10.1016/j.jamcollsurg.2007.07.023

DO - 10.1016/j.jamcollsurg.2007.07.023

M3 - Article

C2 - 18222385

AN - SCOPUS:38349189772

VL - 206

SP - 311

EP - 315

JO - Journal of the American College of Surgeons

JF - Journal of the American College of Surgeons

SN - 1072-7515

IS - 2

ER -